因赛特制药

最新新闻

• Wells Fargo Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $128
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $152
  Benzinga · 2026/9/28
• 公司公告
  4: Incyte | 4: Statement of changes in beneficial ownership of securities-Officer Hoffman Richard A.
  SEC · 2026/7/21
• H.C. Wainwright Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $152
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 公司公告
  Incyte | 4: Statement of changes in beneficial ownership of securities-Director BAKER BROS. ADVISORS LP
  SEC · 2026/5/12
• 公司公告
  Incyte | 4: Statement of changes in beneficial ownership of securities-Director BAKER BROS. ADVISORS LP
  SEC · 2026/10/3
• 评级变动
  CCORF Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $152
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  H.C. Wainwright Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $152
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• BofA Securities Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $140
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  Mizuho Securities Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $137
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 公司公告
  4: Incyte | 4: Statement of changes in beneficial ownership of securities-Director BAKER BROS. ADVISORS LP
  SEC · 2026/7/3
• 评级变动
  H.C. Wainwright Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $150
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  CCORF Initiates Incyte(INCY.US) With Buy Rating, Announces Target Price $152
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• RBC Capital Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $114
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 评级变动
  BMO Capital Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $130
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  William Blair Maintains Incyte(INCY.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  Piper Sandler Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $130
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Leerink Partners Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $155
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 公司公告
  4: Incyte | 4: Statement of changes in beneficial ownership of securities-Director BAKER BROS. ADVISORS LP
  SEC · 2026/6/11
• Stifel Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $157
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target
  Benzinga · 2026/8/3
• 评级变动
  BMO Capital Upgrades Incyte(INCY.US) to Hold Rating, Raises Target Price to $130
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• H.C. Wainwright Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $152
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  H.C. Wainwright Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $150
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 公司公告
  Incyte | 4: Statement of changes in beneficial ownership of securities-Director BAKER BROS. ADVISORS LP
  SEC · 2026/4/3

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。